Review

a498 setd2 homozygous truncating mutation cells (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC a498 setd2 homozygous truncating mutation cells
$(A) The growth response of wild-type S. pombe , set2Δ, wee1-50, paf1Δ, set2Δ wee1-50, set2Δ paf1Δ, and set2Δ wee1-50 paf1Δ was compared by spotting 5-fold serial dilutions of each strain onto YE6S medium. Plates were the incubated for an appropriate time at either 25, 32 or 35.5 °C. ( B-C ) <t>SETD2</t> WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). (D-E) Viability assay to examine the impact of other PAF1 complex factors (including CDC73 and CTR9) silencing on AZD1775-sensitivity. Survival fraction of non-targeting control, CDC73, and CTR9 siRNA treated SETD2 WT and SETD2 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (F) Viability assay to examine the impact of PAF1 silencing on HU or gemcitabine. Survival fraction of non-targeting control and PAF1 siRNA treated SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of HU (150, 300, 600 and 1200 uM) or gemcitabine (12.5, 25, 50 or 100 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (G) Viability assay to examine the sensitivity to HU in gene deletions of PAF1C components in S. pombe .$
A498 Setd2 Homozygous Truncating Mutation Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1633 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a498 setd2 homozygous truncating mutation cells/product/ATCC
Average 97 stars, based on 1633 article reviews

a498 setd2 homozygous truncating mutation cells - by Bioz Stars, 2026-06

97/100 stars

Images

1) Product Images from "R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition"

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

Journal: bioRxiv

doi: 10.1101/2021.07.14.452205

$(A) The growth response of wild-type S. pombe , set2Δ, wee1-50, paf1Δ, set2Δ wee1-50, set2Δ paf1Δ, and set2Δ wee1-50 paf1Δ was compared by spotting 5-fold serial dilutions of each strain onto YE6S medium. Plates were the incubated for an appropriate time at either 25, 32 or 35.5 °C. ( B-C ) SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). (D-E) Viability assay to examine the impact of other PAF1 complex factors (including CDC73 and CTR9) silencing on AZD1775-sensitivity. Survival fraction of non-targeting control, CDC73, and CTR9 siRNA treated SETD2 WT and SETD2 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (F) Viability assay to examine the impact of PAF1 silencing on HU or gemcitabine. Survival fraction of non-targeting control and PAF1 siRNA treated SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of HU (150, 300, 600 and 1200 uM) or gemcitabine (12.5, 25, 50 or 100 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (G) Viability assay to examine the sensitivity to HU in gene deletions of PAF1C components in S. pombe .$
Figure Legend Snippet: (A) The growth response of wild-type S. pombe , set2Δ, wee1-50, paf1Δ, set2Δ wee1-50, set2Δ paf1Δ, and set2Δ wee1-50 paf1Δ was compared by spotting 5-fold serial dilutions of each strain onto YE6S medium. Plates were the incubated for an appropriate time at either 25, 32 or 35.5 °C. ( B-C ) SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). (D-E) Viability assay to examine the impact of other PAF1 complex factors (including CDC73 and CTR9) silencing on AZD1775-sensitivity. Survival fraction of non-targeting control, CDC73, and CTR9 siRNA treated SETD2 WT and SETD2 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (F) Viability assay to examine the impact of PAF1 silencing on HU or gemcitabine. Survival fraction of non-targeting control and PAF1 siRNA treated SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of HU (150, 300, 600 and 1200 uM) or gemcitabine (12.5, 25, 50 or 100 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (G) Viability assay to examine the sensitivity to HU in gene deletions of PAF1C components in S. pombe .

Techniques Used: Incubation, CRISPR, Viability Assay, Control

$(A) Validation of PAF1 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment. (B) Viability assay to examine the impact of PAF1 silencing on AZD1775-sensitivity. Survival fraction of non-targeting control and PAF1 siRNA treated (A-B) 786-0 ( SETD2 WT) and A498 (SETD2-mutant) renal cancer cells. C) Cleaved PARP, procaspase 3, cleaved caspase 3 and actin protein expression in SETD2 WT and SETD2 CRISPR KO U2OS cells 48 hours post-treatment with either 200 nM DMSO or 200 nM AZD1775 was assessed using Western Blot. D) Validation of CDC73 and CTR9 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment.$
Figure Legend Snippet: (A) Validation of PAF1 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment. (B) Viability assay to examine the impact of PAF1 silencing on AZD1775-sensitivity. Survival fraction of non-targeting control and PAF1 siRNA treated (A-B) 786-0 ( SETD2 WT) and A498 (SETD2-mutant) renal cancer cells. C) Cleaved PARP, procaspase 3, cleaved caspase 3 and actin protein expression in SETD2 WT and SETD2 CRISPR KO U2OS cells 48 hours post-treatment with either 200 nM DMSO or 200 nM AZD1775 was assessed using Western Blot. D) Validation of CDC73 and CTR9 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment.

Techniques Used: Biomarker Discovery, Knockdown, Western Blot, CRISPR, Viability Assay, Control, Mutagenesis, Expressing

(A) 48 hours following DMSO or AZD1775-treatment (300 nM), control or siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) Quantification of data shown in (A). (C) SETD2 CRISPR KO U2OS were treated with control or siPAF1 siRNA and exposed to 250 nM of AZD1775 for 48 hours. One representative experiment showing yH2AX vs DNA (left panel) and EdU vs DNA (right panel). The numbers indicate the percentages of cells in the high yH2AX-gated population (shown in black box). These cells correspond with the non-replicating S-phase cells as shown in the EdU plots (blue population). (D) Quantification of the yH2AX medium and high populations shown in (C). (E) Western blot analysis of SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Lamin B was used as a loading control. (F) 48 hr following AZD1775-treatment, control, siCDC73, or siCTR9 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis.

Figure Legend Snippet: (A) 48 hours following DMSO or AZD1775-treatment (300 nM), control or siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) Quantification of data shown in (A). (C) SETD2 CRISPR KO U2OS were treated with control or siPAF1 siRNA and exposed to 250 nM of AZD1775 for 48 hours. One representative experiment showing yH2AX vs DNA (left panel) and EdU vs DNA (right panel). The numbers indicate the percentages of cells in the high yH2AX-gated population (shown in black box). These cells correspond with the non-replicating S-phase cells as shown in the EdU plots (blue population). (D) Quantification of the yH2AX medium and high populations shown in (C). (E) Western blot analysis of SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Lamin B was used as a loading control. (F) 48 hr following AZD1775-treatment, control, siCDC73, or siCTR9 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis.

Techniques Used: Control, Cell Cycle Assay, CRISPR, Western Blot

(A) SETD2 WT and (B) SETD2 CRISPR KO U2OS were treated with control, siCDC73, siCTR9 or siPAF1 and subsequently synchronized at the G 1 /S transition by a double thymidine block (DTB) and then released by addition of fresh medium. Cells were incubated with BrdU for 30 min and collected for cell cycle analysis 4, 8, and 12 hours after release. (C) Western blot analysis of RRM2 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Tubulin was used as a loading control.

Figure Legend Snippet: (A) SETD2 WT and (B) SETD2 CRISPR KO U2OS were treated with control, siCDC73, siCTR9 or siPAF1 and subsequently synchronized at the G 1 /S transition by a double thymidine block (DTB) and then released by addition of fresh medium. Cells were incubated with BrdU for 30 min and collected for cell cycle analysis 4, 8, and 12 hours after release. (C) Western blot analysis of RRM2 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Tubulin was used as a loading control.

Techniques Used: CRISPR, Control, Blocking Assay, Incubation, Cell Cycle Assay, Western Blot

(A) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells after 48 hours of treatment with either non-targeting control siRNA or PAF1 siRNA. Tubulin was used as a loading control. (B) qRT-PCR analysis of CDKN1A levels normalised to 18S in U2OS cells transfected with the indicated siRNAs (n = 3). (C) Western Blot analysis of p-CDK(S) activity following siPAF1 with and without AZD1775 in SETD2 WT U2OS cells. (D) RNA:DNA hybrid slot blot of genomic DNA ± RNaseH1 treatment from cells treated with siNT, siSETD2, siPAF1 or combined siSETD2 and siPAF1. (E) Western blot analysis of p21 protein levels in SETD2 KO U2OS cells. Immunoblot staining for the V5-epitope confirms RNAseH1 overexpression.

Figure Legend Snippet: (A) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells after 48 hours of treatment with either non-targeting control siRNA or PAF1 siRNA. Tubulin was used as a loading control. (B) qRT-PCR analysis of CDKN1A levels normalised to 18S in U2OS cells transfected with the indicated siRNAs (n = 3). (C) Western Blot analysis of p-CDK(S) activity following siPAF1 with and without AZD1775 in SETD2 WT U2OS cells. (D) RNA:DNA hybrid slot blot of genomic DNA ± RNaseH1 treatment from cells treated with siNT, siSETD2, siPAF1 or combined siSETD2 and siPAF1. (E) Western blot analysis of p21 protein levels in SETD2 KO U2OS cells. Immunoblot staining for the V5-epitope confirms RNAseH1 overexpression.

Techniques Used: Western Blot, CRISPR, Control, Quantitative RT-PCR, Transfection, Activity Assay, Dot Blot, Staining, Over Expression

A) 48 hr following DMSO -or AZD1775-treatment, control, siCDKN1A, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. B) 48 hr following DMSO, AZD1775- and/or UC2288 treatment, SETD2 KO U2OS cells were collected for cell cycle analysis. C) SETD2 WT and SETD2 CRISPR KO U2OS cells after 48h exposure to different concentrations of AZD1775 (0-10 μ M) and UCC2288 (p21 inhibitor).

Figure Legend Snippet: A) 48 hr following DMSO -or AZD1775-treatment, control, siCDKN1A, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. B) 48 hr following DMSO, AZD1775- and/or UC2288 treatment, SETD2 KO U2OS cells were collected for cell cycle analysis. C) SETD2 WT and SETD2 CRISPR KO U2OS cells after 48h exposure to different concentrations of AZD1775 (0-10 μ M) and UCC2288 (p21 inhibitor).

Techniques Used: Control, Cell Cycle Assay, CRISPR

$(A) 48 hr following DMSO -or AZD1775-treatment, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) SETD2 CRISPR KO U2OS cells treated with siNT or siPAF1 after 48h exposure to different concentrations of AZD1775 (0-10 μM) and UCC2288 (p21 inhibitor). Survival fraction of non-targeting control, CDC73, and CTR9 (C) siRNA treated TP53 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (D) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or p21 siRNA. Tubulin was used as a loading control. (E) Cell viability is further reduced when WEE1 inhibition is combined with p21 knock down in SETD2 WT and SETD2 mutant cancer cell lines. (F) Model where loss of CDC73, CTR9 and PAF1 results in resistance to WEE1i treatment.$
Figure Legend Snippet: (A) 48 hr following DMSO -or AZD1775-treatment, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) SETD2 CRISPR KO U2OS cells treated with siNT or siPAF1 after 48h exposure to different concentrations of AZD1775 (0-10 μM) and UCC2288 (p21 inhibitor). Survival fraction of non-targeting control, CDC73, and CTR9 (C) siRNA treated TP53 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (D) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or p21 siRNA. Tubulin was used as a loading control. (E) Cell viability is further reduced when WEE1 inhibition is combined with p21 knock down in SETD2 WT and SETD2 mutant cancer cell lines. (F) Model where loss of CDC73, CTR9 and PAF1 results in resistance to WEE1i treatment.

Techniques Used: CRISPR, Control, Western Blot, Inhibition, Knockdown, Mutagenesis

Image Search Results

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) The growth response of wild-type S. pombe , set2Δ, wee1-50, paf1Δ, set2Δ wee1-50, set2Δ paf1Δ, and set2Δ wee1-50 paf1Δ was compared by spotting 5-fold serial dilutions of each strain onto YE6S medium. Plates were the incubated for an appropriate time at either 25, 32 or 35.5 °C. ( B-C ) SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). (D-E) Viability assay to examine the impact of other PAF1 complex factors (including CDC73 and CTR9) silencing on AZD1775-sensitivity. Survival fraction of non-targeting control, CDC73, and CTR9 siRNA treated SETD2 WT and SETD2 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (F) Viability assay to examine the impact of PAF1 silencing on HU or gemcitabine. Survival fraction of non-targeting control and PAF1 siRNA treated SETD2 WT and SETD2 CRISPR KO U2OS cells after 72 h exposure to different concentrations of HU (150, 300, 600 and 1200 uM) or gemcitabine (12.5, 25, 50 or 100 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (G) Viability assay to examine the sensitivity to HU in gene deletions of PAF1C components in S. pombe .

Article Snippet: Human renal cell carcinoma cell lines 786-O ( SETD2 wild-type) were a kind gift from V. Macaulay and A498 (SETD2 homozygous truncating mutation) cells were obtained from ATCC (ATCC number HTB-44).

Techniques: Incubation, CRISPR, Viability Assay, Control

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) Validation of PAF1 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment. (B) Viability assay to examine the impact of PAF1 silencing on AZD1775-sensitivity. Survival fraction of non-targeting control and PAF1 siRNA treated (A-B) 786-0 ( SETD2 WT) and A498 (SETD2-mutant) renal cancer cells. C) Cleaved PARP, procaspase 3, cleaved caspase 3 and actin protein expression in SETD2 WT and SETD2 CRISPR KO U2OS cells 48 hours post-treatment with either 200 nM DMSO or 200 nM AZD1775 was assessed using Western Blot. D) Validation of CDC73 and CTR9 siRNA knockdown efficiency by Western Blot in SETD2 WT and SETD2 CRISPR KO U2OS cells 72 hours post-siRNA treatment.

Techniques: Biomarker Discovery, Knockdown, Western Blot, CRISPR, Viability Assay, Control, Mutagenesis, Expressing

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) 48 hours following DMSO or AZD1775-treatment (300 nM), control or siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) Quantification of data shown in (A). (C) SETD2 CRISPR KO U2OS were treated with control or siPAF1 siRNA and exposed to 250 nM of AZD1775 for 48 hours. One representative experiment showing yH2AX vs DNA (left panel) and EdU vs DNA (right panel). The numbers indicate the percentages of cells in the high yH2AX-gated population (shown in black box). These cells correspond with the non-replicating S-phase cells as shown in the EdU plots (blue population). (D) Quantification of the yH2AX medium and high populations shown in (C). (E) Western blot analysis of SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Lamin B was used as a loading control. (F) 48 hr following AZD1775-treatment, control, siCDC73, or siCTR9 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis.

Techniques: Control, Cell Cycle Assay, CRISPR, Western Blot

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) SETD2 WT and (B) SETD2 CRISPR KO U2OS were treated with control, siCDC73, siCTR9 or siPAF1 and subsequently synchronized at the G 1 /S transition by a double thymidine block (DTB) and then released by addition of fresh medium. Cells were incubated with BrdU for 30 min and collected for cell cycle analysis 4, 8, and 12 hours after release. (C) Western blot analysis of RRM2 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or PAF1 siRNA and/or treated with either DMSO or 300 nM AZD1775. Tubulin was used as a loading control.

Techniques: CRISPR, Control, Blocking Assay, Incubation, Cell Cycle Assay, Western Blot

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells after 48 hours of treatment with either non-targeting control siRNA or PAF1 siRNA. Tubulin was used as a loading control. (B) qRT-PCR analysis of CDKN1A levels normalised to 18S in U2OS cells transfected with the indicated siRNAs (n = 3). (C) Western Blot analysis of p-CDK(S) activity following siPAF1 with and without AZD1775 in SETD2 WT U2OS cells. (D) RNA:DNA hybrid slot blot of genomic DNA ± RNaseH1 treatment from cells treated with siNT, siSETD2, siPAF1 or combined siSETD2 and siPAF1. (E) Western blot analysis of p21 protein levels in SETD2 KO U2OS cells. Immunoblot staining for the V5-epitope confirms RNAseH1 overexpression.

Techniques: Western Blot, CRISPR, Control, Quantitative RT-PCR, Transfection, Activity Assay, Dot Blot, Staining, Over Expression

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: A) 48 hr following DMSO -or AZD1775-treatment, control, siCDKN1A, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells were pulse-labelled with BrdU for 30 min and collected for cell cycle analysis. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. B) 48 hr following DMSO, AZD1775- and/or UC2288 treatment, SETD2 KO U2OS cells were collected for cell cycle analysis. C) SETD2 WT and SETD2 CRISPR KO U2OS cells after 48h exposure to different concentrations of AZD1775 (0-10 μ M) and UCC2288 (p21 inhibitor).

Techniques: Control, Cell Cycle Assay, CRISPR

Journal: bioRxiv

Article Title: R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition

doi: 10.1101/2021.07.14.452205

Figure Lengend Snippet: (A) 48 hr following DMSO -or AZD1775-treatment, siPAF1, or siCDKN1A + siPAF1 treated SETD2 KO U2OS cells. The data shown are from a single representative experiment out of three repeats. Numbers are the relative percentage of cell cycle stage. (B) SETD2 CRISPR KO U2OS cells treated with siNT or siPAF1 after 48h exposure to different concentrations of AZD1775 (0-10 μM) and UCC2288 (p21 inhibitor). Survival fraction of non-targeting control, CDC73, and CTR9 (C) siRNA treated TP53 CRISPR KO cells after 72 h exposure to different concentrations of AZD1775 (75, 150, 300 and 600 nM). Data points and bars represent the mean and SEM of ≥ three independent experiments; * P < 0.05; ** P < 0.01; and *** P < 0.001. (D) Western blot analysis of p21 protein levels in SETD2 WT and SETD2 CRISPR KO U2OS cells exposed to either non-targeting control siRNA or p21 siRNA. Tubulin was used as a loading control. (E) Cell viability is further reduced when WEE1 inhibition is combined with p21 knock down in SETD2 WT and SETD2 mutant cancer cell lines. (F) Model where loss of CDC73, CTR9 and PAF1 results in resistance to WEE1i treatment.

Techniques: CRISPR, Control, Western Blot, Inhibition, Knockdown, Mutagenesis

Review

Structured Review

Images

1) Product Images from "R-loop-induced p21 expression following CDC73, CTR9, and PAF1 loss protects cancer cells against replicative catastrophe following WEE1 inhibition"

Similar Products

Image Search Results